Correction: Enhanced tumorigenicity by mitochondrial DNA mild mutations

Alberto Cruz-Bermúdez; Carmen G. Vallejo; Ramiro J. Vicente-Blanco; María Esther Gallardo; Miguel Ángel Fernández-Moreno; Miguel Quintanilla; Rafael Garesse

doi:10.18632/oncotarget.27522

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Enhanced tumorigenicity by mitochondrial DNA mild mutations

PDF | How to cite

Oncotarget. 2020; 11:1006-1006. https://doi.org/10.18632/oncotarget.27522

Metrics: PDF 1227 views | ?

Alberto Cruz-Bermúdez^1,2,3, Carmen G. Vallejo¹, Ramiro J. Vicente-Blanco^1,2, María Esther Gallardo^1,2,3, Miguel Ángel Fernández-Moreno^1,2,3, Miguel Quintanilla^1,4 and Rafael Garesse^1,2,3

¹ Instituto de Investigaciones Biomédicas “Alberto Sols”, Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Madrid, Spain
² Departamento de Bioquímica and Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Facultad de Medicina, UAM, Madrid, Spain
³ Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), Madrid, Spain
⁴ Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), Madrid, Spain

Published: March 17, 2020

This article has been corrected: The Acknowledgements section has been updated as follows:

ACKNOWLEDGMENTS

This work was supported by the “Instituto de Salud Carlos III” [PI 10/0703 and PI13/00556 to R.G and PI 04/1001 to MAFM]; “Comunidad Autónoma de Madrid” [S2010/BMD-2402 to R.G and S2010/BMD-2359 to MQ); “Fundación Mutua Madrileña” [10.04.02.0064 to MAFM], the Spanish Ministry of Economy and Competitiveness (grant SAF2013-46183-R to MQ) and FEDER funds from the E.U. to R.G. M.E.G. is a staff scientist at the Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Spain. Flow cytometry analyses were carried out at the “Servicio Interdepartamental de Investigacion” (SIdI) with the excellent technical assistance of Laura Molero Martín.

Original article: Oncotarget. 2015; 6:13628–13643. DOI: https://doi.org/10.18632/oncotarget.3698.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27522

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Enhanced tumorigenicity by mitochondrial DNA mild mutations